Gilead Sciences (GILD) PT Raised to $134 at Piper Jaffray on Another 'Beat and Raise'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. BRZE
2. TTAN
3. AAPL
4. CHYM
5. USO
6. QCOM
7. IRT
8. MSI
9. ASO
10. LAES

Go back to Gilead Sciences (GILD) PT Raised to $134 at Piper Jaffray on Another 'Beat and Raise'

Gilead Sciences' (GILD) Price Target Bumped to $135 at Deutsche Bank

July 29, 2015 10:13 AM EDT

Deutsche Bank maintained a Buy rating on Gilead Sciences (NASDAQ: GILD) and raised its price target to $135.00 (from $125.00). Analyst Robyn Karnauskas characterized Q2 results as "solid" and said HCV discounts don't look bad.

"We are lowering our US HCV revenues while increasing OUS numbers & model WW revs at $18.5B vs.... More

Gilead Sciences (GILD) PT Lifted to $135 at Baird on Strong Earnings Beat

July 29, 2015 6:58 AM EDT

Baird analyst Brian Skorney lifted his price target on Outperform-rated Gilead Sciences (NASDAQ: GILD) to $135.00 (from $126.00) following earnings beat.

Skorney commented, "Gilead handily beat expectations, across the board, and raised revenue guidance yet again. Interestingly, nothing in Hep C declined... More

Gilead Sciences (GILD) PT Raised to $120 at Oppenheimer on Solid Q2 Beat

July 29, 2015 6:28 AM EDT

Oppenheimer analyst Wendy Lam reiterated an Outperform rating and boosted her price target on Gilead Sciences (NASDAQ: GILD) to $120.00 (from $86.00) following solid the Q2 beat.

Lam commented, "GILD reported a healthy 2Q15 EPS and product revenues beat ($3.15/$8.13B vs. $2.71/$7.60B consensus) underpinned by... More

Gilead Sciences (GILD) Tops Q2 EPS by 44c

July 28, 2015 4:02 PM EDT

Gilead Sciences (NASDAQ: GILD) reported Q2 EPS of $3.15, $0.44 better than the analyst estimate of $2.71. Revenue for the quarter came in at $8.24 billion versus the consensus estimate of $7.61 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.

... More